Keyphrases
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Chemoradiation
100%
Pneumonitis
100%
Durvalumab
100%
Overall Survival
26%
Progression-free Survival
20%
Chemoradiotherapy
20%
Rechallenge
20%
Prednisone
6%
Median Time
6%
Radiotherapy
6%
Free Survival
6%
Recurring
6%
Multi-institutional
6%
Stage III Disease
6%
Non-small Cell Lung Cancer Patients
6%
Tumor Factor
6%
January 2017
6%
Institutional Review
6%
PACIFIC Trial
6%
Real-world Outcomes
6%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Chemoradiotherapy
100%
Pneumonia
100%
Durvalumab
100%
Overall Survival
26%
Progression Free Survival
20%
Neoplasm
6%
Prednisone
6%
Diseases
6%
Radiation Therapy
6%
Pharmacology, Toxicology and Pharmaceutical Science
Chemoradiation Therapy
100%
Non Small Cell Lung Cancer
100%
Pneumonia
100%
Durvalumab
100%
Overall Survival
26%
Progression Free Survival
20%
Prednisone
6%
Neoplasm
6%
Diseases
6%
Immunology and Microbiology
Pneumonitis
100%
Durvalumab
100%
Overall Survival
26%
Progression Free Survival
20%
Prednisone
6%